About: Mechanism-based Screening for Cancer Therapeutics with Examples from the Discovery of Marine Natural Product-based HIF-1 Inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mechanism-based Screening for Cancer Therapeutics with Examples from the Discovery of Marine Natural Product-based HIF-1 Inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mechanism-based Screening for Cancer Therapeutics with Examples from the Discovery of Marine Natural Product-based HIF-1 Inhibitors
Creator	Nagle, Dale Zhou, Yu-Dong
source	PMC
abstract	Recent advances in cancer genetics combined with an increasing number of new methods in molecular and cell biology provide exciting new antitumor drug targets and a wide array of means to design bioassay systems for the discovery of novel cancer chemotherapeutics. Marine natural products continue to play a vital role in molecular-targeted antitumor drug discovery. Although most recognize the critical and expanding role mechanism-based antitumor bioassays play in modern anticancer drug discovery, few natural products chemists have specific training in bioassay technology. Critical bioassay development factors are outlined and introduced at a level intended to provide a basic understanding to a general audience. These include molecular target identification, antitumor target validation, selection of assayable biochemical processes, data acquisition methods, experimental controls, bioassay validation and statistical methods, experimental artifacts, active compound identification, and the dereplication of nuisance compounds. Marine natural products have been identified that inhibit the activation of the anticancer drug target hypoxia-inducible factor-1 (HIF-1). Bioassay systems and recent results from marine HIF-1 inhibitor discovery programs are used to illustrate important factors that must be considered when using molecular-targeted antitumor bioassay methods.
has issue date	2012-01-23(xsd:dateTime)
bibo:doi	10.1007/978-90-481-3834-0_22
has license	no-cc
sha1sum (hex)	ae8ab88c9d7d891f5bd4927ef0a1ca51a6175acd
schema:url	https://doi.org/10.1007/978-90-481-3834-0_22
resource representing a document's title	Mechanism-based Screening for Cancer Therapeutics with Examples from the Discovery of Marine Natural Product-based HIF-1 Inhibitors
has PubMed Central identifier	PMC7119942
schema:publication	Handbook of Marine Natural Products
resource representing a document's body	covid:ae8ab88c9d7d891f5bd4927ef0a1ca51a6175acd#body_text
is schema:about of	named entity 'Natural' named entity 'Mechanism-based' named entity 'hypoxic conditions' named entity 'pathophysiological' named entity 'statistical significance' named entity 'HIF-1a' named entity 'HIF-1a' named entity 'spectroscopic data' named entity 'HIF-1' named entity 'bioassays' named entity 'target gene' named entity 'erythropoiesis' named entity 'biochemical' named entity 'HIF' named entity 'fluorescence' named entity 'small interfering RNA' named entity 'metastasis' named entity 'cell proliferation' named entity 'hydroxylation' named entity 'sponge' named entity 'angiogenic' named entity 'HIF' named entity 'phenotype' named entity 'drug discovery' named entity 'cell-based assays' named entity 'enzyme' named entity 'quercetin' named entity 'HIF-1a' named entity 'HIF-1' named entity 'aryl hydrocarbon receptor nuclear translocator' named entity 'T47D' named entity 'HIF-1' named entity 'oncogenes' named entity 'hypoxia' named entity 'tumor cells' named entity 'lipid' named entity 'bioassay' named entity 'siRNA' named entity 'natural products' named entity 'tumor hypoxia' named entity 'kinase' named entity 'molecular techniques' named entity 'HIF-1' named entity 'T47D' named entity 'molecular and cell biology' named entity 'HIF-1' named entity 'bioassays' named entity 'polypeptide' named entity 'HIF' named entity 'T47D' named entity 'gene' named entity 'solid tumors' named entity 'cytotoxic' named entity 'Molecular target' named entity 'SciFinder' named entity 'heterodimer' named entity 'cytotoxins' named entity 'taxonomic' named entity 'hypoxic' named entity 'high-throughput screening' named entity 'rat' named entity 'meiosis' named entity 'natural products' named entity 'HIF-1a' named entity 'tumor suppressor genes' named entity 'total synthesis' named entity 'chemotaxonomic' named entity 'HIF' named entity 'prognosis' named entity 'isomers' named entity 'mitochondrial electron transport chain' named entity 'natural product' named entity 'tumor cells' named entity 'tumor progression' named entity 'Assay' named entity 'luminescent' named entity 'HIF-1' named entity 'molecular target' named entity 'hypoxic' named entity 'biochemical' named entity 'biological systems' named entity 'HIF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software